Skip to main navigation Skip to search Skip to main content

Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1

  • Priya Ragunathan
  • , Thomas Dick
  • , Gerhard Grüber

Research output: Contribution to journal › Article › peer-review

Abstract

New drug targets and molecules with bactericidal activity are needed against the respiratory mycobacterial pathogen Mycobacterium abscessus. Employing a lead repurposing strategy, the antituberculosis compound GaMF1 was tested against M. abscessus. Whole-cell and ATP synthesis assays demonstrated that GaMF1 inhibits growth and kills M. abscessus by targeting the F-ATP synthase. GaMF1's anti- M. abscessus activity increased in combination with clofazimine, rifabutin, or amikacin. The study expands the repertoire of anti-M. abscessus compounds targeting oxidative phosphorylation.

Original languageEnglish (US)
JournalAntimicrobial agents and chemotherapy
Volume66
Issue number5
DOIs
StatePublished - May 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Keywords

  • FATP synthase,g subunit inhibitor
  • Mycobacterium abscessus
  • bioenergetics
  • multidrug resistance
  • nontuberculous mycobacteria

Fingerprint

Dive into the research topics of 'Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1'. Together they form a unique fingerprint.

Cite this